These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1053 related items for PubMed ID: 18471782

  • 21. Stepping-stones to the further advancement of androgen-deprivation therapy for prostate cancer.
    Nishiyama T, Suzuki K, Yamana K, Tonegawa E, Wako K, Takahashi K.
    Expert Rev Anticancer Ther; 2006 Feb; 6(2):259-68. PubMed ID: 16445378
    [Abstract] [Full Text] [Related]

  • 22. Androgen receptor: role and novel therapeutic prospects in prostate cancer.
    Taplin ME.
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1495-508. PubMed ID: 18759700
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
    Soga N, Arima K, Sugimura Y.
    Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
    [Abstract] [Full Text] [Related]

  • 25. The benefits of early androgen blockade.
    Maroni PD, Crawford ED.
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):317-29. PubMed ID: 18471789
    [Abstract] [Full Text] [Related]

  • 26. Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP.
    Hinotsu S, Akaza H, Usami M, Ogawa O, Kagawa S, Kitamura T, Tsukamoto T, Naito S, Namiki M, Hirao Y, Murai M, Yamanaka H, Japan Study Group of Prostate Cancer (J-CaP).
    Jpn J Clin Oncol; 2007 Oct; 37(10):775-81. PubMed ID: 17965423
    [Abstract] [Full Text] [Related]

  • 27. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients.
    Gannon PO, Poisson AO, Delvoye N, Lapointe R, Mes-Masson AM, Saad F.
    J Immunol Methods; 2009 Aug 31; 348(1-2):9-17. PubMed ID: 19552894
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. A re-assessment of the role of combined androgen blockade for advanced prostate cancer.
    Klotz L, Schellhammer P, Carroll K.
    BJU Int; 2004 Jun 31; 93(9):1177-82. PubMed ID: 15180600
    [No Abstract] [Full Text] [Related]

  • 31. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T, Nutahara K, Higashihara E.
    J Urol; 2008 Oct 31; 180(4):1342-7. PubMed ID: 18707699
    [Abstract] [Full Text] [Related]

  • 32. Maximal androgen blockade versus total androgen suppression.
    Dumez H, Van Poppel H, Baert L, Paridaens R.
    Acta Urol Belg; 1997 Mar 31; 65(1):49-54. PubMed ID: 9175283
    [Abstract] [Full Text] [Related]

  • 33. Maximum vs. mono androgen blockade and the risk of recurrence in men with localized prostate cancer undergoing brachytherapy.
    Chen RC, Sadetsky N, Chen MH, Carroll PR, D'Amico AV.
    Int J Radiat Oncol Biol Phys; 2009 Sep 01; 75(1):36-9. PubMed ID: 19233568
    [Abstract] [Full Text] [Related]

  • 34. Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer.
    DiBlasio CJ, Malcolm JB, Derweesh IH, Womack JH, Kincade MC, Mancini JG, Ogles ML, Lamar KD, Patterson AL, Wake RW.
    BJU Int; 2008 Jul 01; 102(1):39-43. PubMed ID: 18294309
    [Abstract] [Full Text] [Related]

  • 35. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T, Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group.
    J Urol; 2008 Sep 01; 180(3):921-7. PubMed ID: 18635218
    [Abstract] [Full Text] [Related]

  • 36. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a Japanese perspective--the effect of primary androgen deprivation therapy on stage C prostate cancer.
    Akaza H.
    BJU Int; 2007 Jan 01; 99 Suppl 1():10-2; discussion 17-8. PubMed ID: 17229161
    [Abstract] [Full Text] [Related]

  • 37. Overview of current status of total androgen deprivation in metastasized prostate cancer.
    Debruyne FM, Witjes WP.
    Eur Urol; 1993 Jan 01; 24 Suppl 2():67-71. PubMed ID: 8262129
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. [Disseminated carcinoma of the prostate: monotherapy or complete androgenic blockade?].
    González Martín M, Gómez Veiga F, Alvarez Castelo L.
    Arch Esp Urol; 1997 Dec 01; 50(10):1067-76. PubMed ID: 9494195
    [Abstract] [Full Text] [Related]

  • 40. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
    DiBlasio CJ, Malcolm JB, Hammett J, Wan JY, Aleman MA, Patterson AL, Wake RW, Derweesh IH.
    BJU Int; 2009 Nov 01; 104(9):1208-14. PubMed ID: 19388987
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 53.